The cardiovascular effects of nebulized adenosine in man

M. O. Coupe; B. Clarke; A. Robson; P. J. Oldershaw; P. J. Barnes

doi:10.1007/BF00615231

The cardiovascular effects of nebulized adenosine in man

M. O. Coupe, B. Clarke, A. Robson, P. J. Oldershaw, P. J. Barnes

Research output: Contribution to journal › Article › peer-review

Abstract

We have studied the cardiovascular effects of inhaled adenosine in healthy subjects. Adenosine at a concentration of 5 mg·ml-1 is absorbed and produces an increase in heart rate of 6-7 beats per min, blood pressure and skin temperature being unaltered. The rise in heart rate is less than that seen with an infusion of a comparable dose and is unlikely to be adequate for therapeutic termination of supraventricular tachycardia. Higher doses are limited by the poor solubility of adenosine. Inhalation as a method of delivering adenosine has possibilities as an alternative route of administration, but some practical problems remain to be overcome. © 1988 Springer-Verlag.

Original language	English
Pages (from-to)	645-647
Number of pages	2
Journal	European journal of clinical pharmacology
Volume	34
Issue number	6
DOIs	https://doi.org/10.1007/BF00615231
Publication status	Published - Nov 1988

Keywords

adenosine
cardiovascular effects
nebulizer

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/BF00615231

Cite this

@article{de800f0e63294e8f9e2f4a9cf9fde5a3,

title = "The cardiovascular effects of nebulized adenosine in man",

abstract = "We have studied the cardiovascular effects of inhaled adenosine in healthy subjects. Adenosine at a concentration of 5 mg·ml-1 is absorbed and produces an increase in heart rate of 6-7 beats per min, blood pressure and skin temperature being unaltered. The rise in heart rate is less than that seen with an infusion of a comparable dose and is unlikely to be adequate for therapeutic termination of supraventricular tachycardia. Higher doses are limited by the poor solubility of adenosine. Inhalation as a method of delivering adenosine has possibilities as an alternative route of administration, but some practical problems remain to be overcome. {\textcopyright} 1988 Springer-Verlag.",

keywords = "adenosine, cardiovascular effects, nebulizer",

author = "Coupe, {M. O.} and B. Clarke and A. Robson and Oldershaw, {P. J.} and Barnes, {P. J.}",

year = "1988",

month = nov,

doi = "10.1007/BF00615231",

language = "English",

volume = "34",

pages = "645--647",

journal = "European journal of clinical pharmacology",

issn = "0031-6970",

publisher = "Springer Nature",

number = "6",

}

TY - JOUR

T1 - The cardiovascular effects of nebulized adenosine in man

AU - Coupe, M. O.

AU - Clarke, B.

AU - Robson, A.

AU - Oldershaw, P. J.

AU - Barnes, P. J.

PY - 1988/11

Y1 - 1988/11

N2 - We have studied the cardiovascular effects of inhaled adenosine in healthy subjects. Adenosine at a concentration of 5 mg·ml-1 is absorbed and produces an increase in heart rate of 6-7 beats per min, blood pressure and skin temperature being unaltered. The rise in heart rate is less than that seen with an infusion of a comparable dose and is unlikely to be adequate for therapeutic termination of supraventricular tachycardia. Higher doses are limited by the poor solubility of adenosine. Inhalation as a method of delivering adenosine has possibilities as an alternative route of administration, but some practical problems remain to be overcome. © 1988 Springer-Verlag.

AB - We have studied the cardiovascular effects of inhaled adenosine in healthy subjects. Adenosine at a concentration of 5 mg·ml-1 is absorbed and produces an increase in heart rate of 6-7 beats per min, blood pressure and skin temperature being unaltered. The rise in heart rate is less than that seen with an infusion of a comparable dose and is unlikely to be adequate for therapeutic termination of supraventricular tachycardia. Higher doses are limited by the poor solubility of adenosine. Inhalation as a method of delivering adenosine has possibilities as an alternative route of administration, but some practical problems remain to be overcome. © 1988 Springer-Verlag.

KW - adenosine

KW - cardiovascular effects

KW - nebulizer

U2 - 10.1007/BF00615231

DO - 10.1007/BF00615231

M3 - Article

C2 - 3169116

SN - 0031-6970

VL - 34

SP - 645

EP - 647

JO - European journal of clinical pharmacology

JF - European journal of clinical pharmacology

IS - 6

ER -

The cardiovascular effects of nebulized adenosine in man

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this